Horizon 1 1 17 ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES Antimicrobial Agents and Chemotherapy e01686-18 [5 p.] pregnancy tenofovir hepatitis B virus pharmacokinetics THAILANDE 2018 fdi:010074806 ENG Antimicrobial Agents and Chemotherapy 0066-4804 ISI:000451216800051 12 10.1128/aac.01686-18 https://www.documentation.ird.fr/hor/fdi:010074806 https://www.documentation.ird.fr/intranet/publi/2018/12/010074806.pdf 62 Horizon (IRD) We assessed tenofovir exposure during pregnancy and postpartum in hepatitis B virus (HBV)-infected HIV-uninfected women receiving tenofovir disoproxil fumarate (TDF) to prevent mother-to-child transmission of HBV. Data from 154 women who received TDF within a randomized controlled trial were included. Individual plasma tenofovir exposures (area under the concentration-time curve from 0 to 24 h [AUC0-24]) were estimated using a population pharmacokinetic approach. The estimated geometric mean tenofovir AUC(0-24) was 20% (95% confidence interval [95% CI], 19 to 21%) lower during pregnancy than during postpartum; this modest reduction in the absence of HBV transmission suggests that no dose adjustment is needed. 052 ; 050 UR174 Thaïlande